CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome


      • High CRLF2 reduces B-cell differentiation in Down syndrome mouse progenitor cells.
      • High CRLF2 is associated with less B-cell differentiation in human leukemia cells.
      • High CRLF2 is associated with E2F signaling in Down syndrome mouse and human cells.
      • Inhibitors of E2F signaling are cytotoxic in CRLF2+ acute lymphoblastic leukemia.
      • High CRLF2 in Dp16 cells is not sufficient to generate leukemia in recipient mice.
      Children with Down syndrome (DS) are 10-fold more likely to develop B-cell acute lymphoblastic leukemia (B-ALL), with a higher frequency of rearrangements resulting in overexpression of cytokine receptor-like factor 2 (CRLF2). Here, we investigated the impact of CRLF2 overexpression on B-cell progenitor proliferation, immunophenotype, and gene expression profile in the Dp(16)1Yey (Dp16) mouse model of DS compared with wild-type (WT) mice. CRLF2 overexpression enhanced immature B-lymphoid colony development and increased the proportion of less differentiated pre-pro-B cells, with a greater effect in Dp16 versus WT. In CRLF2-rearranged (CRLF2-R) B-ALL patient samples, cells with higher CRLF2 expression exhibited a less differentiated B-cell immunophenotype. CRLF2 overexpression resulted in a gene expression signature associated with E2F signaling both in Dp16 B-progenitors and in DS-ALL patient samples, and PI3K/mTOR and pan-CDK inhibitors, which reduce E2F-mediated signaling, exhibited cytotoxicity in CRLF2-R B-ALL cell lines and patient samples. CRLF2 overexpression alone in Dp16 stem and progenitor cells did not result in leukemic transformation in recipient mice. Thus, CRLF2 overexpression results in reduced B-cell differentiation and enhanced E2F signaling in Dp16 B-progenitor cells and DS-ALL patient samples. These findings suggest a functional basis for the high frequency of CRLF2-R in DS-ALL as well as a potential therapeutically targetable pathway.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Experimental Hematology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Buitenkamp TD
        • Izraeli S
        • Zimmermann M
        • et al.
        Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
        Blood. 2014; 123: 70-77
        • Hasle H
        • Clemmensen IH
        • Mikkelsen M.
        Risks of leukaemia and solid tumours in individuals with Down's syndrome.
        Lancet. 2000; 355: 165-169
        • Mullighan CG
        • Collins-Underwood JR
        • Phillips LA
        • et al.
        Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
        Nat Genet. 2009; 41: 1243-1246
        • Russell LJ
        • Capasso M
        • Vater I
        • et al.
        Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
        Blood. 2009; 114: 2688-2698
        • Bercovich D
        • Ganmore I
        • Scott LM
        • et al.
        Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
        Lancet. 2008; 372: 1484-1492
        • Gaikwad A
        • Rye CL
        • Devidas M
        • et al.
        Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
        Br J Haematol. 2009; 144: 930-932
        • Hertzberg L
        • Vendramini E
        • Ganmore I
        • et al.
        Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
        Blood. 2010; 115: 1006-1017
        • Roberts KG
        • Li Y
        • Payne-Turner D
        • et al.
        Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
        N Engl J Med. 2014; 371: 1005-1015
        • O'Connor D
        • Bate J
        • Wade R
        • et al.
        Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
        Blood. 2014; 124: 1056-1061
        • Patrick K
        • Wade R
        • Goulden N
        • et al.
        Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
        Br J Haematol. 2014; 165: 552-555
        • Li Z
        • Yu T
        • Morishima M
        • et al.
        Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities.
        Hum Mol Genet. 2007; 16: 1359-1366
        • Roy A
        • Cowan G
        • Mead AJ
        • et al.
        Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.
        Proc Natl Acad Sci USA. 2012; 109: 17579-17584
        • Lane AA
        • Chapuy B
        • Lin CY
        • et al.
        Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
        Nat Genet. 2014; 46: 618-623
        • Lorenzo LP
        • Chen H
        • Shatynski KE
        • et al.
        Defective hematopoietic stem cell and lymphoid progenitor development in the Ts65Dn mouse model of Down syndrome: potential role of oxidative stress.
        Antioxid Redox Signal. 2011; 15: 2083-2094
        • Hardy RR
        • Shinton SA.
        Characterization of B lymphopoiesis in mouse bone marrow and spleen.
        Methods Mol Biol. 2004; 271: 1-24
        • Wang H
        • Lee CH
        • Qi C
        • et al.
        IRF8 regulates B-cell lineage specification, commitment, and differentiation.
        Blood. 2008; 112: 4028-4038
        • Cho SK
        • Webber TD
        • Carlyle JR
        • Nakano T
        • Lewis SM
        • Zuniga-Pflucker JC.
        Functional characterization of B lymphocytes generated in vitro from embryonic stem cells.
        Proc Natl Acad Sci USA. 1999; 96: 9797-9802
        • Liberzon A
        • Birger C
        • Thorvaldsdottir H
        • Ghandi M
        • Mesirov JP
        • Tamayo P.
        The Molecular Signatures Database (MSigDB) hallmark gene set collection.
        Cell Syst. 2015; 1: 417-425
        • Loudin MG
        • Wang J
        • Leung HC
        • et al.
        Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.
        Leukemia. 2011; 25: 1555-1563
        • Ghelli Luserna Di Rora A
        • Beeharry N
        • Imbrogno E
        • et al.
        Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
        J Hematol Oncol. 2018; 11: 99
        • Aimiuwu J
        • Wang H
        • Chen P
        • et al.
        RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
        Blood. 2012; 119: 5229-5238
        • Schwartzman O
        • Savino AM
        • Gombert M
        • et al.
        Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
        Proc Natl Acad Sci USA. 2017; 114: E4030-E4039
        • Schwab CJ
        • Chilton L
        • Morrison H
        • et al.
        Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.
        Haematologica. 2013; 98: 1081-1088
        • Kent LN
        • Leone G.
        The broken cycle: E2F dysfunction in cancer.
        Nat Rev Cancer. 2019; 19: 326-338
        • Ma Y
        • Kurtyka CA
        • Boyapalle S
        • et al.
        A small-molecule E2F inhibitor blocks growth in a melanoma culture model.
        Cancer Res. 2008; 68: 6292-6299
        • Michaloglou C
        • Crafter C
        • Siersbaek R
        • et al.
        Combined Inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer.
        Mol Cancer Ther. 2018; 17: 908-920
        • Romero-Pozuelo J
        • Figlia G
        • Kaya O
        • Martin-Villalba A
        • Teleman AA.
        Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1.
        Cell Rep. 2020; 31107504
        • Zhou X
        • Liu W
        • Hu X
        • et al.
        Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells.
        Sci Rep. 2017; 7: 1535
        • Chae HD
        • Mitton B
        • Lacayo NJ
        • Sakamoto KM.
        Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.
        Leukemia. 2015; 29: 1379-1389